Avastin-Injections in Age Related Macular Degeneration: Prospective Study for Optimal Frequency and Follow-up Determinatio
Phase 2
Completed
- Conditions
- age-related macular degeneration10047060
- Registration Number
- NL-OMON31474
- Lead Sponsor
- Oogziekenhuis Rotterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 360
Inclusion Criteria
- Informed consent
- Endophthalmitis risks have been made clear
- No preference to paritcipate in the Infliximab for ARMD trial
- Age >= 65 years
- Exudative subfoveolar age related macular degeneration
- No significant other ocular disorders affecting visual acuity
- Not immunocompromised
- No allergy for fluorescein or ICG dye injections
- No treatment for ARMD or other retinal problem in the 3 months prior to trial start
- No planned ocular surgery in the first year after trial start
Exclusion Criteria
- Use of coumarin-derivatives at the time of inclusion
- Clinical significant CVA or MCI in the 6 months prior to planned inclusion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Visual acuity at 12 months.<br /><br>OCT outcomes at 12 months.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Endophthalmitis and other side effects frequency.</p><br>